PRPascal Rathelot

Pascal Rathelot

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pascal Rathelot has a total of 116 co-authors. Here are the top co-authors by number of shared publications:

  • Patrice Vanelle

    CNRS, ICR UMR 7273, Team Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Aix Marseille University, 27 Boulevard Jean Moulin, CS30064, CEDEX 05, 13385 Marseille, France

    15 shared publications
  • Nicolas Primas

    Aix Marseille Univ, CNRS, ICR UMR 7273, Team Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, 13385 Marseille, France; Service Central de la Qualité et de l'Information Pharmaceutiques, Hôpital de la Conception, AP-HM, 13005 Marseille, France

    10 shared publications
  • Nadine Azas

    IHU Méditerranée Infection, UMR VITROME-Tropical Eukaryotic Pathogens, Aix Marseille University, 19–21 Boulevard Jean Moulin, 13005 Marseille, France

    7 shared publications
  • Pierre Verhaeghe

    LCC-CNRS Université de Toulouse, CNRS, UPS, Toulouse, France

    6 shared publications
  • Caroline Castera-Ducros

    CNRS, ICR UMR 7273, Team Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Aix Marseille University, 27 Boulevard Jean Moulin, CS30064, CEDEX 05, 13385 Marseille, France

    5 shared publications
  • Caroline Castera-Ducros

    Service Central de la Qualité et de l'Information Pharmaceutiques (SCQIP), Assistance Publique - Hôpitaux de Marseille, CHU Conception, 147 boulevard Baille, 13005 Marseille, France; Aix-Marseille Université, CNRS, Institut de Chimie Radicalaire ICR, UMR 7273, Equipe Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, 27 boulevard Jean Moulin, 13005 Marseille, France

    4 shared publications

Latest Publications

  • Open Access

    Hard Gelatin Capsules Compounded and Dispersed in Water in Pediatrics: Real Versus Theoretical Dose Administered

    by Romain Paoli-Lombardo, Nicolas Primas, Clémence Tabélé, Ikram Zaddam, Eya Iben Slimene, Pascal Rathelot, Patrice Vanelle, Caroline Castera-Ducros, Christophe Curti

    Background: In pediatric practice, dose individualization often requires the manipulation of solid oral dosage forms, such as dispersing capsules in water and administering only part of the volume. Despite its frequent use, this practice is poorly documented and may lead to inaccurate dosing. Objectives: This study aimed to assess the actual dose administered when compounded hard gelatin capsules are dispersed in water and partially withdrawn, and to evaluate the influence of different manipulation protocols on dose recovery. Methods: Ten active pharmaceutical ingredients (APIs) routinely compounded as pediatric hard gelatin capsules were studied. Content uniformity was first verified according to European Pharmacopoeia (EP) requirements. One capsule was dispersed in 2 mL of water, and 1 mL was withdrawn using three protocols: (1) no mixing, (2) gentle manual mixing with immediate sampling, and (3) gentle manual mixing followed by a 10 s resting period before sampling. Drug content in the withdrawn volume was quantified using validated HPLC-UV methods. Results are expressed as the mean percentage of the theoretical dose ± standard deviation. Results: All capsules complied with EP content uniformity criteria. However, partial volume administration resulted in marked and protocol-dependent deviations from the theoretical dose. Without mixing, recovered doses ranged from 17% to 58% of the target dose, with high variability. Gentle mixing improved dose recovery, particularly for APIs forming solutions, such as captopril, thiamine hydrochloride, and clonidine hydrochloride, which achieved values close to 90%. In contrast, APIs forming suspensions consistently resulted in underdosing, even after mixing, with further reductions observed after a short resting period, indicating rapid sedimentation. Conclusions: Fractional administration of dispersed hard gelatin capsules leads to unpredictable and often clinically relevant underdosing, especially for poorly soluble APIs. Whenever possible, capsules should be compounded at the prescribed dose, and liquid formulations should be preferred when dose fractionation is required.


  • Former les équipes de soins d’un CHU multi-sites à la problématique des médicaments à haut risque : utilisation d’un escape game

    by Pierre Leroux, Caroline Castera-Ducros, Laurence Conreur, Said Ait Taleb, Adja Fatou Diack, Louise Cayez, Romain Paoli-Lombardo, Édouard Lamy, Nicolas Primas, Christophe Curti, et al.


  • Open Access

    Formulation, Quality Control and Stability Study of Pediatric Oral Dextrose Gel

    by Edouard Lamy, Caroline Orneto, Oumil Her Abdou Ali, Lyna Kireche, Fanny Mathias, Cyrielle Bouguergour, Florence Peyron, Nicolas Primas, Christophe Sauzet, Philippe Piccerelle, et al.

    Background/Objective: Little information is available on the stability and quality controls of compounded 40% dextrose gel required to ensure its safe use in the treatment and prevention of neonatal hypoglycemia. Whether its efficacy relies on buccal absorption also remains uncertain. This study investigates the stability, microbiological safety, rheological properties and dextrose diffusion of a compounded 40% oral dextrose gel, ensuring it can be widely compounded and stored for clinical use. Methods: A 40% dextrose gel compounded with anhydrous dextrose, carboxymethylcellulose, citric acid, sorbic acid and sterile water was subjected to quality control measures including a dextrose content assay, degradation product analysis, microbiological testing and preservative efficacy. Stability studies were conducted at refrigerated (4–8 °C) and ambient temperatures for 7 days and 3 months, respectively. Rheological properties were assessed, and dextrose permeation was measured through an artificial membrane model that mimics a biological membrane. Results: The compounded gel demonstrated stability for up to 7 days at ambient temperature and 90 days when refrigerated. The dextrose content remained within the acceptable range (90–110%) and microbiological tests confirmed compliance with safety standards. The gel exhibited the consistent rheological properties and shear-thinning behavior appropriate for oral mucosal administration. In vitro permeation studies showed no evidence of dextrose diffusion with a long lag time followed by a low steady-state permeation flux. Conclusions: This study validates the compounding process of a stable 40% oral dextrose gel formulation for neonatal hypoglycemia management, which meets quality control criteria and can be safely administered in clinical practice, offering a cost-effective and safe alternative for neonatal care.


  • Analyse du livret thérapeutique des médicaments d’un CHU pour développer la prescription hospitalière de médicaments exécutée en ville dans le répertoire des génériques

    by Govind Kallee, Saïd Ait Taleb, Pierre Leroux, Caroline Castera-Ducros, Florent Lanet, Patrice Vanelle, Pierre Ambrosi, Pascal Rathelot

  • Open Access

    From the “One-Molecule, One-Target, One-Disease” Concept towards Looking for Multi-Target Therapeutics for Treating Non-Polio Enterovirus (NPEV) Infections

    by Hugo Roux, Franck Touret, Pascal Rathelot, Patrice Vanelle, Manon Roche

    Non-polio enteroviruses (NPEVs), namely coxsackieviruses (CV), echoviruses (E), enteroviruses (EV), and rhinoviruses (RV), are responsible for a wide variety of illnesses. Some infections can progress to life-threatening conditions in children or immunocompromised patients. To date, no treatments have been approved. Several molecules have been evaluated through clinical trials without success. To overcome these failures, the multi-target directed ligand (MTDL) strategy could be applied to tackle enterovirus infections. This work analyzes registered clinical trials involving antiviral drugs to highlight the best candidates and develops filters to apply to a selection for MTDL synthesis. We explicitly stated the methods used to answer the question: which solution can fight NPEVs effectively? We note the originality and relevance of this proposal in relation to the state of the art in the enterovirus-inhibitors field. Several combinations are possible to broaden the antiviral spectrum and potency. We discuss data related to the virus and data related to each LEAD compound identified so far. Overall, this study proposes a perspective on different strategies to overcome issues identified in clinical trials and evaluate the “MTDL” potential to improve the efficacy of drugs, broaden the antiviral targets, possibly reduce the adverse effects, drug design costs and limit the selection of drug-resistant virus variants.


  • Open Access

    From the “One Molecule – One Target – One Disease” Concept towards Looking for Multi-target Therapeutics for Treating Non-polio Enterovirus (Npev) Infections

    by Hugo Roux, Franck Touret, Pascal Rathelot, Patrice Vanelle, Manon Roche

    Non-polio enteroviruses (NPEVs), namely coxsackieviruses (CV), echoviruses (E), enteroviruses (EV), and rhinoviruses (RV), are responsible for a wide variety of illnesses. Some infections can progress to life-threatening complications in children or immunocompromised patients. To date, no treatments have been approved. Several molecules have been evaluated through clinical trials without success. To overcome these failures, the multi-target directed ligand (MTDL) strategy can be applied to tackle enterovirus infections. This work analyzes clinical trials to highlight the best candidates and develops filters to apply to a selection for MTDL synthesis. We explicitly stated the methods used to answer the question: Which solution can fight NPEVs effectively? We note the originality and relevance of this proposal in relation to the state of the art in the enterovirus-inhibitors field. Several combinations are possible to broaden the antiviral spectrum and potency. We discuss data related to the virus and data related to each LEAD compound identified. Overall, this study proposes a perspective on different strategies to overcome issues identified in clinical trials and evaluate the “MTDL” potential to improve the efficiency of drugs synergistically, broaden the targeted, and reduce the adverse effects and drug design cost as well as limit the opportunity of drug-resistant viruses.


  • Open Access

    31st Annual GP2A Medicinal Chemistry Conference

    by Nicolas Primas, Caroline Castera-Ducros, Romain Paoli-Lombardo, Christophe Curti, Fanny Mathias, Pascal Rathelot, Pascal Marchand, Patrice Vanelle

    The Group for the Promotion of Pharmaceutical Chemistry in Academia (GP2A) held its 31st annual conference in August 2023 at the Faculty of Pharmacy of Aix-Marseille University, Marseille, France. There were 8 keynote presentations, 10 early career researcher oral presentations and 23 poster presentations. Among them, four awards were delivered, two for best oral communications and two for the best poster presentations.


  • Open Access

    N-[1-(2-Chlorophenyl)-2-{1-methyl-5-nitro-4-[(phenylsulfonyl)methyl]-1H-imidazol-2-yl}ethyl]-4-methylbenzenesulfonamide

    by Romain Paoli-Lombardo, Nicolas Primas, Caroline Castera-Ducros, Inès Jacquet, Pascal Rathelot, Patrice Vanelle

    In continuation of our research program to develop original synthetic methods using TDAE methodology on nitroheterocyclic substrates, we were able to generate for the first time a stable carbanion in position 2 of the 5-nitroimidazole scaffold. Starting from a 2-chloromethyl-4-phenylsulfonylmethyl-5-nitroimidazole intermediate, prepared by the vicarious nucleophilic substitution of hydrogen (VNS) reaction, we selectively introduced a N-tosylbenzylimine moiety at position 2 without reducing the sulfone at position 4, leading to the formation of N-[1-(2-chlorophenyl)-2-{1-methyl-5-nitro-4-[(phenylsulfonyl)methyl]-1H-imidazol-2-yl}ethyl]-4-methylbenzenesulfonamide in 47% yield. This new synthetic method using TDAE should allow access to new 2-substituted 5-nitroimidazole derivatives with various electrophiles such as carbonyls and other N-tosylbenzylimines.


  • Open Access

    6-Chloro-3-nitro-8-(phenylthio)-2-[(phenylthio)methyl] imidazo[1,2-a]pyridine

    by Romain Paoli-Lombardo, Nicolas Primas, Sébastien Hutter, Sandra Bourgeade-Delmas, Clotilde Boudot, Caroline Castera-Ducros, Inès Jacquet, Bertrand Courtioux, Nadine Azas, Pascal Rathelot, et al.

    As part of our ongoing antikinetoplastid structure–activity relationship study focused on positions 2 and 8 of the 3-nitroimidazo[1,2-a]pyridine scaffold, we were able to introduce a phenylthioether moiety at both position 2 and position 8 in one step. Using a previously reported synthetic route developed in our laboratory, we obtained 6-chloro-3-nitro-8-(phenylthio)-2-[(phenylthio)methyl]imidazo[1,2-a]pyridine in 74% yield. The in vitro cell viability of this compound was assessed on the HepG2 cell line, and its in vitro activity was evaluated against the promastigote form of L. donovani, the axenic amastigote form of L. infantum and the trypomastigote blood stream form of T. b. brucei. It showed low solubility in HepG2 culture medium (CC50 > 7.8 µM), associated with weak activity against both the promastigote form of L. donovani (EC50 = 8.8 µM), the axenic amastigote form of L. infantum (EC50 = 9.7 µM) and the trypomastigote blood stream form of T. b. brucei (EC50 = 12.8 µM).

  • Open Access

    6-Chloro-3-nitro-2-[(phenylsulfonyl)methyl]imidazo[1,2-b]pyridazine

    by Romain Paoli-Lombardo, Nicolas Primas, Sébastien Hutter, Sandra Bourgeade-Delmas, Clotilde Boudot, Caroline Castera-Ducros, Inès Jacquet, Bertrand Courtioux, Nadine Azas, Pascal Rathelot, et al.

    As part of our ongoing scaffold-hopping work on an antikinetoplastid 3-nitroimidazo[1,2-a]pyridine scaffold, we explored 3-nitroimidazo[1,2-b]pyridazine as a potential new antikinetoplastid series. Using conditions previously described by our lab, we obtained 6-chloro-3-nitro-2-[(phenylsulfonyl)methyl]imidazo[1,2-b]pyridazine with 54% yield. In vitro activity of this compound was evaluated against both the promastigote form of Leishmania donovani, the axenic amastigote form of Leishmania infantum and the trypomastigote blood stream form of Trypanosomabrucei brucei, and its influence on cell viability was assessed on the HepG2 cell line. However, despite good activity against the trypomastigote blood stream form of T. b. brucei (EC50 = 0.38 µM), it showed poor solubility in both HepG2 (CC50 > 7.8 µM) and L. infantum axenic amastigotes (EC50 > 1.6 µM) culture media, associated with a loss of activity against the promastigote form of L. infantum (EC50 > 15.6 µM).